scholarly journals The Impact of Core Tissues on Successful Next-Generation Sequencing Analysis of Specimens Obtained through Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5879
Author(s):  
Keigo Uchimura ◽  
Komei Yanase ◽  
Tatsuya Imabayashi ◽  
Yuki Takeyasu ◽  
Hideaki Furuse ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Success Rate ◽  
Needle Aspiration ◽  
Endobronchial Ultrasound ◽  
Sequencing Analysis ◽  
Next Generation ◽  
Ultrasound Guided ◽  
Transbronchial Needle Aspiration ◽  
Generation Sequencing

The success rate of next-generation sequencing (NGS) with specimens obtained through endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) among patients with lung cancer as well as the related clinical factors remain unclear. We aimed to determine the optimal number of punctures and core tissues during EBUS-TBNA for NGS in patients with non-small-cell lung cancer (NSCLC) as well as the association of chest computed tomography (CT) and EBUS findings with successful NGS. We retrospectively reviewed 156 consecutive patients with NSCLC who underwent EBUS-TBNA for NGS (OncomineTM Dx Target Test). Using the receiver operating characteristic curve, we calculated the optimal numbers of punctures and core tissues for NGS and evaluated CT and EBUS findings suggestive of necrosis and vascular pattern within the lesion. The success rate of NGS was 83.3%. The cut-off value for the number of core tissues was 4, and the sensitivity and specificity of successful NGS were 73.8% and 61.5%, respectively. Logistic regression analysis revealed that the number of core tissues (≥4) was the sole predictor of successful NGS. CT and EBUS findings were not associated with successful NGS. Bronchoscopists should obtain sufficient core tissues for successful NGS using EBUS-TBNA specimens.

scholarly journals Acquired Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound–Guided Transbronchial Needle Aspiration Samples

2018 ◽  
Vol 142 (4) ◽  
pp. 465-473 ◽  
Author(s):  
Elena Guerini-Rocco ◽  
Antonio Passaro ◽  
Chiara Casadio ◽  
Valeria Midolo De Luca ◽  
Juliana Guarize ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Tyrosine Kinase ◽  
Needle Aspiration ◽  
Small Cell ◽  
Endobronchial Ultrasound ◽  
Small Cell Lung ◽  
Ultrasound Guided ◽  
Transbronchial Needle Aspiration ◽  
Lung Cancers ◽  
Generation Sequencing

Context.— Molecular testing is essential for the diagnostic workup of patients with advanced non–small cell lung cancers. Cytology specimens from minimally invasive procedures, such as endobronchial ultrasound–guided transbronchial needle aspiration, are often the only available samples for these patients. The implementation of molecular diagnostic testing, and in particular next-generation sequencing–based testing, on these cytologic specimens is currently an evolving field for lung cytopathology. The application of these molecular analyses on tyrosine kinase inhibitor–resistant non–small cell lung cancers raises unique technical, biologic, and clinical challenges. Objective.— To provide an overview of the implementation of next-generation sequencing analysis on endobronchial ultrasound–guided transbronchial needle aspiration samples to detect the molecular aberrations underneath the phenomenon of acquired resistance in patients with non–small cell lung cancers progressing while on the EGFR/ALK tyrosine kinase inhibitor treatment. Data Sources.— Peer-reviewed original articles, review articles, and published guidelines and expert opinion reports were reviewed, together with our single-center experience. Conclusions.— Next-generation sequencing analyses and the endobronchial ultrasound–guided transbronchial needle aspiration procedure may represent a valuable strategy to address the unique requirements of molecular testing on tyrosine kinase inhibitor–resistant non–small cell lung cancers.

Next-generation sequencing for genetic analysis of endobronchial ultrasound transbronchial needle aspiration samples in advanced lung cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15586-e15586
Author(s):  
Xianjun Min ◽  
Mingwei Li ◽  
Qiang Liu ◽  
Yingshun Yang ◽  
Guotian Pei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Squamous Cell ◽  
Needle Aspiration ◽  
Endobronchial Ultrasound ◽  
Advanced Lung Cancer ◽  
Genetic Mutations ◽  
Transbronchial Needle Aspiration ◽  
Tissue Samples ◽  
Generation Sequencing

e15586 Background: Next-generation sequencing (NGS) typically requires greater quantities of DNA than traditional molecular testing. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) is a minimally invasive technique with high sensitivity in the mediastinal staging of lung cancer. This study aimed to evaluate the adequacy of EBUS-TBNA in providing adequate size specimens for genetic mutations and immunotherapy biomarkers analysis in patients with lung cancer. Methods: Tissue samples from patients with advanced lung cancer were collected by EBUS-TBNA and were formalin-fixed paraffin-embedded. NGS assay was carried on with acornmed panel including 808 genes. PD-L1 expression through immunohistochemistry was assessed. Results: A total of 98 patients was enrolled, of which 74 (76%) were adenocarcinoma and 20 (20%) were squamous cell carcinomas. Among the patients, 108 samples (including multipoint puncture of different location and retest of the same patient) were obtained. NGS assay was completed successfully on 106 of the 108 samples (98.14%), and 97.96% of patients had successful testing, identifying an average of 11.3 mutations. With a multi-gene panel comprising up to 808 tumor related genes, actionable variations were found in 93 (86%) samples. Of these, the positive rates of actionable alterations in lung adenocarcinoma samples and lung squamous cell carcinoma samples were 90% and 79%, respectively. The tumor mutation burden (TMB), Microsatellite instability (MSI) and PD-L1 expression were found High in 20 (41%), 1 (2%), and 37 (72%) patients respectively. Conclusions: NGS assay can be successfully conducted with tissue samples obtained from EBUS-TBNA. NGS assay provides more comprehensive information on genetic mutations in tumors, which greatly assists therapeutic decision making for advanced lung cancer.

Sign in / Sign up

Export Citation Format

Share Document